N aive T cells require signals from the costimulatory receptor CD28 for full activation, differentiation, and immune function. CD4 + T cells that experience TCR signaling in the absence of costimulation induce negative regulators of multiple TCR-coupled signaling pathways. For instance, diacylglycerol kinases, caspases, and E3 ubiquitin ligases target PLCg-1, Vav, and PKC for proteolysis, resulting in defective activation of the MAPK, IKK, and PI3K cascades upon re-encounter with Ag (reviewed in Ref. 1) . This active inhibitory state is referred to as anergy, and a loss of any of these negative regulators leads to defects in the acquisition of peripheral tolerance. Anergic T cells also upregulate an inhibitor of the cyclin-dependent kinase (CDK) cascade, p27kip1 (2, 3) . T cells deficient for the gene encoding p27kip1 fail to become anergic when stimulated in the absence of costimulation (4) , and mice with a loss of p27kip1 function are highly resistant to tolerance induced by costimulatory blockade in vivo (5, 6) . Therefore, p27kip1 appears to be a key regulator of peripheral tolerance, but it is unclear whether p27kip1 functions in this capacity as a CDK inhibitor or influences tolerance as a result of other, CDK-independent functions. p27kip1 also binds to RhoA and inhibits actin polymerization and focal adhesion (7) , processes important for T cell activation and migration, and it can inhibit the activity of c-Jun, a crucial factor for transcription of the il2 gene, by binding to the c-Jun coactivator Jab1 (8) . A deletion mutant of p27kip1 that lacks the CDKbinding domain was shown to be defective in anergy induction (6) . However, this mutant also lacks a serine residue that is critical for its interaction with Jab1 (9), for its subcellular localization (10) , and for protein stability (8) . Therefore, the mechanism by which p27kip1 contributes to tolerance, as well as the potential role of CDK in the balance between tolerance and immunity, has not been addressed.
In the current study, we directly targeted CDK2, the major CDK regulated by p27kip1, to determine its role in T cell immunity versus tolerance. Earlier biochemical work indicated that CDK2 was critical for progression from the G 1 phase to the S phase of the cell cycle. However, more recent studies in mice genetically deficient for individual or multiple CDK family members showed that CDK1 is the major driver of cell cycle progression, whereas CDK2, CDK4, and CDK6 have supportive roles and specialized, cell cycle-independent functions (reviewed in Ref. 11) . Using a combination of genetic and chemical approaches, we demonstrate that CDK2 is dispensable for CD4 + T cell proliferation and instead contributes to optimal activation and differentiation. Loss of CDK2 function in vivo resulted in increased susceptibility to organ transplant tolerance induced by costimulatory blockade. Allograft survival in CDK2-deficient recipients was associated with reduced frequencies of donor-specific, IFN-g-producing T cells and increased regulatory T cell (Treg) function. Our results demonstrate that CDK2 controls the balance between immunity and tolerance by regulating both conventional T cell (Tconv) and Treg function.
Association of Laboratory Animal Care-approved institutional guidelines on animal care and usage. CDK2-deficient mice on a 129S1/SvlmJxC57BL/ 6 background (12) were obtained from P. Kaldis (Institute of Molecular and Cell Biology, Singapore) and were back-crossed to B6 for 9-10 generations. All mice were used at 5-12 wk of age.
Measurement of in vitro T cell activation and cytokine production
Single-cell suspensions of spleen and lymph node were depleted of CD8 + T cells using magnetic beads (Miltenyi Biotec) and cultured for 24-72 h with soluble, agonistic anti-CD3 mAb (2C11, 0.5 mg/ml) in the presence of either agonistic anti-CD28 (37-51, 0.5 mg/ml) or CTLA-4Ig (5 mg/ml; all from BioExpress). Following primary stimulation, CD4 + T cells were purified by positive selection on magnetic beads (Miltenyi Biotec), rested overnight in medium, and restimulated on plate-bound anti-CD3/28 mAb for 4-24 h. IL-2 and IFN-g in supernatants harvested during primary and secondary cultures were detected using quantitative ELISA kits (eBioscience). In some experiments, the CDK2-selective inhibitors roscovitine (Calbiochem), alsterpaullone (Calbiochem), and NU6140 
Retroviral short hairpin RNA transduction
A short hairpin RNA (shRNA) sequence (59-CCGGAAGATGGACGGAG-CTTGTTATCTCGAGATAACAAGCTCCGTCCATCTTTTTTTG-39) targeting the CDK2 transcript was cloned into the pMKO1 vector and used to transduce CD4 + T cells, as described previously (13) . A control, nonspecific shRNA targeting human cyclin D3 (14) was also constructed. Knock-down of CDK2 was confirmed by immunoblot analysis of transduced T cells using a CDK2-specific mAb (Cell Signaling Technologies).
Quantitative PCR analysis of mRNA transcripts
2 (Tconv) and CD4 + CD25 + (Treg) were purified from spleen and lymph node using magnetic beads (Miltenyi Biotec). Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA), and reverse transcription was performed using the iScript Select cDNA synthesis kit (Bio-Rad). Specific mRNA transcripts were quantified using SYBR Green on a StepOnePlus real-time thermal cycler (Applied Biosystems, Foster City, CA). Expression levels were calculated for each sample by first normalizing to 18S rRNA and then normalizing to unstimulated CD4 +
CD25
2 cells using the standard d-d CT method.
In vivo mixed lymphocyte response
Alloreactive T cell proliferation was assessed in an in vivo allogeneic mixed lymphocyte response, as described previously (15 ) recipient mice. Recipients were treated with either CTLA4-Ig or control Ig fusion protein i.p. (100 mg/mouse) on days 0 and 1. Recipient spleens were harvested on day 3, donor lymphocytes were identified by flow cytometry on the basis of their lack of H-2 d , and CFSE dilution in the CD4 + subset was measured. Gating procedures for all parameters allowed ,1% false positives in negative control samples.
Cardiac transplantation
Studies were performed as described previously (5) . Briefly, fully mismatched BALB/c (H-2 d ) hearts were transplanted heterotopically into WT or CDK2-deficient 129S1/SvlmJ 3 C57BL/6 (H-2 b ) mice. The donor ascending aorta and pulmonary artery were anastomosed end-to-side to the recipient infrarenal aorta and inferior vena cava. CTLA-4Ig or control Ig fusion protein (200 mg; BioExpress) was administered i.p. on days 0, 2, and 4 posttransplant. Graft survival was assessed by abdominal palpation, and rejection was defined as total cessation of cardiac contraction confirmed by histology. Statistical analysis of allograft survival was analyzed using Kaplan-Meier/log-rank methods.
Histology and immunohistology
At the time of harvest, portions of the grafts were fixed in formalin for paraffin sectioning or snap-frozen for subsequent immunohistologic analysis. H&E-stained paraffin sections were evaluated using the revised International Society of Heart and Lung Transplantation standardized criteria for grading of cardiac allograft biopsies. Heart tissue was fixed, sectioned, and stained with H&E or with Ab against CD3 (Epitomics), CD8 (Epitomics), CD4 (Epitomics), Foxp3 (eBiosciences), CDK2 (Santa Cruz Biotech), or cyclin A (Santa Cruz Biotech). Primary Ab were visualized using secondary HRP conjugates and Envision kits (Dako). Cells positive for each stain were counted within 10-15 high-power fields (HPF) in sections from four allografts/group, and data were compared using an unpaired t test.
ELISPOT assay
ELISPOT assays were performed as previously described (5) . Briefly, Immunospot assays for IFN-g were performed by coating ELISPOT plates (BD Pharmingen) with anti-IFN-g mAb, followed by blocking, and splenocytes from transplant recipients (1 3 10 5 , 2 3 10 5 , or 4 3 10 5 cells/ well) were placed in each well, with donor splenocytes from BALB/c mouse as stimulator cells. After 24 h, cells were discarded and wells were washed, followed by use of anti-IFN-g mAb, streptavidin-HRP, and substrate reaction. Spots were counted automatically using an ImmunoSpot Analyzer (Cellular Technology). The p values were calculated by a Student paired t test using Prism software (GraphPad).
In vitro Treg suppression
+ mice, and CD90 2 APC were isolated from total splenocytes using magnetic bead-conjugated mAbs (Miltenyi Biotec). APC (1 3 10 5 ) were irradiated (1000 rad) and plated onto 96-well plates along with effector cells (5 3 10 4 /well) labeled with CFSE and 4 mg/ml soluble anti-CD3 mAb. Treg were added to each well, in various Treg/effector cell ratios, and cultured for 72 h. After 3 d, suppression of responder cell proliferation was determined by assessing the degree of inhibition of CFSE dilution by flow cytometry. 
Adoptive-transfer colitis model

Results
CDK2 is not required for CD4 + T cell cycle progression
As a primary approach to induce a loss of CDK2 function, we used mice deficient for CDK2 (12) . Hematopoiesis, lymphoid development, and lymphocyte homeostasis are normal in CDK2-deficient mice (16) ; therefore, these mice represent a good model in which to study the role of CDK2 in adaptive-immune responses. We first tested whether the lack of CDK2 in CD4 + T cells resulted in defective cell cycle progression in response to mitogenic signaling. WT and CDK2-deficient CD4 + T cells divided comparably in cultures of CD8-depleted spleen cells stimulated in vitro with agonistic anti-TCR Ab (Fig. 1) . This is consistent with previous studies showing that fibroblasts from mice devoid of either CDK2 or cyclin E activity show a delay in S phase entry but, overall, proliferate normally (12, 17) . From these results, we conclude that CDK2 is dispensable for essentially normal proliferation of activated CD4 cells.
CDK2 promotes cytokine production by CD4 + T cells
The inhibitory partner of CDK2, p27kip1, acts as a sensor of mitogenic signals from CD28 and IL-2R, and CD4 + T cells genetically deficient for p27kip1 differentiate even in the absence of costimulation (1) . Therefore, we predicted that CD4 + T cells deficient for CDK2 would show an opposite phenotype (i.e., these cells should have problems integrating signals from the TCR and CD28 for cytokine production). Despite normal activation, proliferation, and survival, CDK2-deficient CD4 + T cells exhibited decreased production of IL-2 and IFN-g in response to primary stimulation, both in the presence and absence of CD28 costimulation ( Fig. 2A, 2B ). This does not reflect a developmental defect, because acute inhibition of CDK2 activity in WT CD4 + T cells also repressed the production of IL-2 and IFN-g. Treatment of WT T cells with three small molecule inhibitors of CDK2 (roscovitine, NU6140, and alsterpaullone), but not with a CDK1 inhibitor (indolylmethylene-2-indolinone), led to a dose-dependent decrease in IL-2 production (Fig. 2C) . Similarly, knock-down of CDK2 in WT CD4 + T cells using shRNA also led to reduced expression of IL-2 and IFN-g at both the protein (Fig. 2D ) and mRNA level (data not shown).
T cells that have been primed through the TCR and CD28 (Fig.  2F, 2H , dark gray circles) are able to secrete IL-2 and IFN-g more rapidly and robustly than are naive cells (Fig. 2E, 2G , dark gray circles) when stimulated. However, primed CDK2-deficient cells exhibited a significant defect in the production of IL-2 (Fig. 2F , light gray circles), comparable to the anergic response observed in (Fig. 2F,  dark gray squares) . CDK2-deficient CD4 cells also showed a marked delay in IFN-g secretion (Fig. 2H, light gray circles) , and blockade of costimulation during priming completely abrogated the differentiation of these cells into IFN-g producers (Fig. 2H,  light gray squares) . The mechanism by which CDK2 is coupled to cytokine gene expression is unclear. CDK2-deficient CD4 + T cells showed no defects in the expression of factors involved in the transactivation of the il2 promoter, such as NFAT1, NF-kB p65, Fos, or c-Jun, at the mRNA level, nor did these cells show elevated expression of anergy-associated genes, such as Egr-2, Egr-3, Itch, Grail, Cbl-b, or Ikaros (N. Chunder and A. Wells, unpublished observations). Additional experiments will be needed to establish how CDK2 contributes to the control of cytokine gene expression.
CDK2 promotes acute alloimmune T cell responses and contributes to costimulatory blockade-resistant allograft rejection in vivo
Our previous studies showed that the CDK2 inhibitory protein p27kip1 is required for transplantation tolerance induced by combined costimulatory blockade (5). To address whether CDK2 itself has a role in the alloimmune response, we first used a parentinto-F1 MLR model to measure allospecific T cell activation and expansion in vivo (15) . A high frequency of alloreactive donor CD4 + T cells from WT B6 mice showed robust expansion when adoptively transferred into semiallogeneic B6 3 DBA2 recipients (Fig. 3) , and blockade of CD28 costimulation resulted in a marked decrease in alloreactive T cell division (Fig. 3A) and expansion (Fig. 3B) . Donor alloreactive CD4 + T cells lacking CDK2 divided as well as WT donor cells in recipients treated with control Ig (Fig. 3A) , further emphasizing that CDK2 activity is not required for efficient T cell cycle progression. However, CDK2-deficient alloreactive T cells failed to accumulate in the spleen (Fig. 3B) , suggesting that CDK2 may contribute to the survival or trafficking of proliferating T cells in vivo. Whereas alloreactive T cells lacking p27kip1 enjoy a significant proliferative advantage over WT cells under conditions of costimulatory blockade (4), CDK2-deficient T cells exhibited a near-complete failure to divide and expand in CTLA-4Ig-treated recipients (Fig. 3) .
Next, we transplanted WT or CDK2-deficient mice with fully mismatched BALB/c cardiac allografts. In the absence of treatment, the kinetics of allograft survival in both groups were equivalent, with both WT and CDK2-deficient mice rejecting their grafts within 7 d posttransplant (Fig. 4A, black symbols) . Blockade of the CD28 costimulatory pathway in WT recipients using CTLA-4Ig provided a significant benefit, but all grafts were eventually rejected, with a mean survival ∼30 d (Fig. 4A, blue  symbols) . The frequency of donor-specific, IFN-g-producing CD4
+ T cells was similar in the spleens of untreated recipients (Fig. 4B) ; however, CDK2-deficient recipients treated with CTLA-4Ig exhibited 5-fold fewer donor-specific IFN-g-producing cells than did WT recipients (Fig. 4C) . Histologic analysis of cardiac allografts harvested at 30 d posttransplant from WT recipients treated with CTLA-4Ig showed diffuse mononuclear cell infiltration with arteritis and areas of focal myocyte necrosis (Fig. 4D, left panel) , and infiltrates consisted of a mixture of CD4 + and CD8 + T cells plus small numbers of Foxp3 + mononuclear cells (Fig. 4E, left panels) . Mononuclear cells infiltrating the grafts in WT recipients treated with CTLA-4Ig showed strong expression of CDK2 and the CDK2-dependent protein cyclin A (Fig. 4F , left panels), indicating that the CDK pathway is highly active in immune cells during allograft rejection. In contrast, costimulatory blockade in CDK2-deficient recipients resulted in long-term allograft acceptance, with all recipients retaining their allografts for .100 d (p , 0.001) (Fig. 4A, red symbols) . At 30 d posttransplant, these grafts exhibited normal cardiac histology with well-preserved vasculature and an absence of myocyte necrosis (Fig. 4D, right  panel) . CD4
+ and CD8 + T cell infiltrates were observed at 30 d posttransplant, but they tended to occur in perivascular areas rather than more diffusely as was seen in WT recipients, and they were accompanied by a 2-fold increase in the number of infiltrating Foxp3 + mononuclear cells (Fig. 4 E, + cells in the thymus, lymph nodes, and spleen (data not shown). In addition, mononuclear cells infiltrating the allografts in CDK2-deficient recipients not only lacked expression of CDK2, they were almost completely devoid of cyclin A expression (Fig. 4F, right panels) . These results demonstrate that the CDK2 pathway is active during an alloimmune response, where it has a role in driving the differentiation and effector function of alloreactive CD4 + T cells. As predicted, this is opposite of the role of the inhibitor p27kip1 (5), suggesting that p27kip1 is required for allograft tolerance largely because of its ability to restrain CDK2 activity.
CDK2 opposes Treg function
To address whether the Treg in CDK2-deficient mice exhibit a gain of suppressive function, we isolated CD4 + CD25 + cells from naive, WT, or CDK2-deficient mice and measured their ability to inhibit naive CD4 + T cell proliferation in a standard, in vitro suppression assay. At all ratios tested, CDK2-deficient Treg exhibited an enhanced capacity to suppress the proliferation of WT CD4 + T cells, representing an ∼3-fold increase in efficiency (Fig. 5A, solid red  line) . In addition, CD4 + Tconv from CDK2-deficient mice were slightly more susceptible to suppression by WT Treg compared with WT Tconv (Fig. 5A, dotted blue line) . The combination of CDK2-deficient Treg against CDK2-deficient Tconv, which simulates the circumstance in intact CDK2-deficient mice, showed the strongest level of suppression (Fig. 5A, dotted red lines) . These data demonstrate that CDK2 acts in a cell-intrinsic manner to restrict Treg suppressive capacity in vitro. The mechanistic basis for this is not clear; however, Treg lacking CDK2 exhibited a moderate increase in the expression of several genes involved in Treg function, including CD25, STAT5, GITR, PD-1, SMAD3, and TGFb (Fig. 5B) .
To determine whether CDK2 controls Treg function in vivo, we tested the capacity of WT versus CDK2-deficient Treg to suppress colitis mediated by naive CD4 + T cells in a murine model of inflammatory bowel disease (18) . Colitis was first induced in immunodeficient (Rag1 2/2 ) mice by adoptive transfer of WT naive CD4 + T cells. Recipients began to exhibit symptoms of disease ∼18 d posttransfer; at day 20, animals were randomized and received PBS as a control or a therapeutic dose of CD4 + CD25 + Treg from either WT or CDK2-deficient mice. Mock-treated animals continued to lose weight and exhibit severe diarrhea and wasting over the next 40 d (Fig. 5C, red line) , whereas recipients of WT Treg began to recover within 10 d and showed markedly reduced . Cardiac allograft response in WT versus CDK2-deficient mice. (A) WT (squares) or CDK2-deficient (circles) mice were transplanted with BALB/c cardiac grafts and treated with control Ig (n = 3, black lines) or CTLA-4Ig (n = 6-7, colored lines), and graft survival was observed over a 100-d period. In a separate experiment, groups of three WT or CDK2-deficient mice were transplanted and treated as in (A) and sacrificed at day 32 posttransplant. The p values were calculated by ANOVA. CD4 + T cells purified from the spleens of control Ig-treated (B) and CTLA-4Ig-treated (C) recipients were stimulated with BALB/c splenocytes in vitro, and the frequency of donor-specific cells was determined by ELISPOT. Allograft tissue harvested from CTLA-4Ig-treated recipients was sectioned and stained with H&E (D), Abs against CD4, CD8, and Foxp3 (E), or Abs against CD3, CDK2, and cyclin A (F) Original magnification 3350 (D-F).
symptoms of disease by day 50 (Fig. 5C, green line) . Mice that received CDK2-deficient Treg began to recover rapidly within 5 d (Fig. 5C , blue line) and no longer suffered from wasting or diarrhea; by day 30, their weight was indistinguishable from control animals receiving no naive CD4 + T cells (Fig. 5C , black line). These mice showed significantly reduced gross and histologic pathology in the colon (e.g., reduced thickening and hemorrhaging of the intestinal wall) compared with recipients of WT Treg (data not shown). Together, these data show that CDK2 acts in a cell-intrinsic manner to control the capacity of Treg to inhibit Tconv proliferation and immunopathogenesis.
Discussion
TCR signaling in the absence of costimulation results in active suppression of several kinase cascades. For example, diacylgycerol kinases deplete the secondary messenger diacylglycerol, and E3 ubiquitin ligases, such as Itch and Cbl-b, target PLCg-1 and PKC for proteolysis, together resulting in defective activation of downstream MAPK pathways (1) . In addition, the phosphatase PTEN opposes the activity of PI3K (19) , and p27kip1 binds to and inhibits the activity of the CDK2-cyclin E holoenzyme (3) . Like the other negative regulators listed above, p27kip1 is required for the induction of anergy (4), but its exact role in this process has been unclear. Although p27kip1 is clearly a potent CDK inhibitor, it also has CDK-independent functions in the cell. For instance, p27kip1 was shown to bind RhoA and inhibit actin polymerization and focal adhesion (7), and it can inhibit the activity of c-Jun by binding to its coactivator, Jab1 (8) . Our results demonstrate that CDK2 activity is required for normal cytokine production by CD4 + T cells in vitro, as well as for full alloimmune T cell differentiation and effector function in vivo. This indicates that dysregulated CDK2 activity in p27kip1-deficient mice (20) (21) (22) directly contributes to the enhanced T cell responses in these animals (4, 23, 24) and to their resistance to tolerance induction (5, 6) .
Unicellular eukaryotes, such as Schizosaccharomyces pombe, encode a single, ancestral CDK, Cdc2a, which is sufficient for mitotic cell division in these organisms (reviewed in Ref. 25) . Multicellular eukaryotes encode an ortholog of Cdc2a, termed CDK1, but they also express multiple additional CDK (e.g., CDK2, CDK4, CDK5, CDK6). These interphase CDK are thought to play successive roles in promoting cell cycle progression; however, recent studies on mice lacking individual interphase CDK indicated that these factors are not required for cellular proliferation. Indeed, embryonic development and organogenesis proceed through embryonic day 13.5 in mice with compound genetic deficiency for CDK2, CDK3, CDK4, CDK5, and CDK6, and mouse embryonic fibroblasts from these animals can proliferate and undergo transformation in vitro. These results show that CDK1 is sufficient for essential cell cycle progression, whereas interphase CDK appear to have evolved primarily to promote the differentiation of specialized tissues (26) . For example, mice lacking CDK2 show normal growth and development, but they cannot undergo meiosis; therefore, they exhibit defects in ovarian development and spermatogenesis (12, 27) . Similarly, our results indicate that CDK2 is not required for the proliferation or the survival of CD4 + T cells, but it is necessary for normal T cell differentiation. Based upon the phenotype of CD4 + T cells lacking the CDK-inhibitory protein p27kip1, which behave as though they have received an anergy avoidance signal even when they have not (4, 6), CDK2 was proposed to act as a cell-intrinsic anergyavoidance sensor (1, 6, 28) . We now show direct genetic evidence that, in the absence of CDK2 activity, CD4 + T cells enter a hyporesponsive state even when stimulated in the presence of signals that normally allow T cells to escape anergy. Still, it is not clear whether the reduced capacity of T cells to rapidly produce IL-2 and IFN-g when primed in the absence of CDK2 is truly reflective of anergy. Anti-CD3/28-activated CDK2-deficient cells do not exhibit an anergic transcript profile, and the addition of exogenous IL-2 does not rescue the defect in cytokine production (N. Chunder and A. Wells, unpublished observations). Therefore, it is possible that the defect instead reflects a failure in differentiation and memory (i.e., the capacity of cells to epigenetically or transcriptionally poise cytokine loci for rapid expression upon restimulation). More studies will be required to distinguish between these two possibilities.
It is clear from multiple studies that complete blockade of CD28 costimulation, either by the saturating doses of CTLA-4Ig used in this study or by genetic deletion of CD28, is not sufficient to block allograft rejection (e.g., Fig. 4A ). Thus, in WT mice, CDK2 must be able to cooperate with other receptors to promote graft rejection. These may include alternative costimulatory receptors, such as CD40L or ICOS, or growth factor receptors for IL-2 or other g c -coupled cytokines. In fact, Th differentiation is highly influenced by IL-2R-coupled signaling. IL-2 inhibits Th17 and follicular helper T cells differentiation (29) (30) (31) , whereas it promotes anergy avoidance (1), drives Th1 and Th2 development (32) (33) (34) (35) , and cooperates with TGF-b to induce Foxp3 in inducible Treg (36, 37) . IL-2 is thought to mediate these effects largely through its capacity to activate STAT5, which directly promotes the expression of IL-4, IL-12R, Tbet, IFN-g, and Foxp3, and it can antagonize the binding of STAT3 and the expression of Bcl-6. Our study demonstrates that receptors for other factors distinct from CD28 must also signal through CDK2 to drive Th1 differentiation and control Treg function.
How might CDK2 be acting to regulate Tconv differentiation and Treg function? In addition to proteins involved in DNA replication and mitosis, CDK2 is known to phosphorylate DNA-binding proteins, such as c-Jun (38), Runx1 (39, 40) , Sp1 (41, 42) , and Smad3 (43) , all of which can regulate transcription from the il2 promoter. CDK2 was also shown to regulate transcriptional and chromatin regulatory cofactors, such as CBP/p300 (44), EZH2 (45) , and histone H1 (46, 47) . Studies in CDK1-only mice led to the hypothesis that interphase CDK must act on crucial, cell typespecific substrates (26) . Although CDKs were shown to regulate the lymphocyte-specific Rag proteins during lymphocyte development (48), mature T lymphocyte-specific substrates have not been reported. In the case of Treg, the most obvious lineagespecific substrate would be Foxp3. Interestingly, the murine Foxp3 protein contains four putative CDK substrate motifs (S/TP followed by one or more basic residues), and we have preliminary evidence that CDK2-cyclin E can phosphorylate Foxp3 in vitro (N. Chunder and A. Wells, unpublished observations). Additional studies will be required to establish the biochemical mechanism(s) by which CDK2 influences T cell differentiation and Treg function.
These findings are therapeutically relevant to transplantation and autoimmune disease, because many kinase inhibitors have been successfully implemented in the clinic, and roscovitine (seliciclib) is currently in clinical trials for the treatment of cancer. Although the short half-life of roscovitine has hampered in vivo studies in preclinical models (49) , this CDK2-inhibitory drug was recently shown to block alloimmune pathology in a murine model of graftversus-host disease (50) . Therefore, CDK may serve as novel immunomodulatory targets in the treatment of immunopathologic disease.
